American Society for Dermatologic Study (ASDS) Annual Meeting 2022

Venus Bliss™ is cleared by the FDA for non-invasive lipolysis of the abdomen and flanks in individuals with a Body Mass Index (BMI) of 30 or less, with the diode laser applicators. The (MP)² applicator is cleared by the FDA for temporary reduction in the appearance of cellulite.

Venus Versa™ is cleared by the FDA as a multi-application device intended to be used in aesthetic and cosmetic procedures. The SR515 and SR580 applicators are cleared by the FDA for the treatment of benign pigmented epidermal and cutaneous lesions and treatment of benign cutaneous vascular lesions. The HR650/HR650XL and HR690/HR690XL applicators are cleared by the FDA for the removal of unwanted hair and to effect stable long-term or permanent hair reduction for Fitzpatrick skin types I-IV. The AC Dual applicator is cleared by the FDA for the treatment of acne vulgaris. The DiamondPolar™ and OctiPolar™ applicators on the Venus Versa™ system are cleared by the FDA for non-invasive treatment of moderate to severe facial wrinkles and rhytides on females with Fitzpatrick skin types I-IV. The NanoFractional RF™ (Viva) applicator is cleared by the FDA for dermatological procedures requiring ablation and resurfacing of the skin.

ARTAS iX™ is cleared by the FDA with indication for use for harvesting hair follicles from the scalp in men diagnosed with androgenic alopecia (male pattern hair loss) who have black or brown straight hair. ARTAS iX™ is intended to assist physicians in identifying and extracting hair follicular units from the scalp during hair transplantation; creating recipient sites; and implanting harvested hair follicles.

NeoGraft^® is cleared by the FDA with indication for use in suction-assisted follicular extraction and re-implantation. NeoGraft^® is an auto-graft system and can be used on both male and female patients.

Venus Legacy™ is cleared by the FDA for the non-invasive treatment of moderate to severe facial wrinkles and rhytides in females with Fitzpatrick skin types I-IV with the OctiPolar™ and DiamondPolar™ applicators, and temporary reduction in the appearance of cellulite with the 4D Body (LB2) and 4D Face (LF2) applicators.

Venus Velocity™ is cleared by the FDA for hair removal, permanent hair reduction (defined as the long-term stable reduction in the number of hairs re-growing when measured at 6, 9 and 12 months after the completion of a treatment regimen), and the treatment of pseudofolliculitis barbae, for all Fitzpatrick skin types.

The Venus Viva™ MD is cleared by the FDA for the use in dermatological procedures requiring ablation and resurfacing of the skin, and the non-invasive treatment of moderate to severe facial wrinkles and rhytides for females in Fitzpatrick skin types I-IV with the DiamondPolar™ applicator.

Venus Freeze Plus™ is a non-invasive device cleared by the FDA for use in dermatologic and general surgical procedures for females for the treatment of moderate to severe facial wrinkles and rhytides in Fitzpatrick skin types I-IV, using the DiamondPolar™ and OctiPolar™ applicators.

Venus Heal™ is cleared by the FDA for the relief of minor muscle aches and pain, relief of muscle spasm, and temporary improvement of local blood circulation. The treatment of these conditions will lead to the treatment of certain soft tissue injuries and conditions.

Venus Glow™ is cleared by the FDA as a Class I motorized dermabrasion device. It provides a dermal rejuvenation treatment that works to open up and deep-clean pores. Venus Concept is the exclusive distributor for Venus Glow™.

Venus Epileve™ is cleared by the FDA for hair removal, permanent hair reduction (defined as the long-term stable reduction in the number of hairs
re-growing when measured at 6, 9 and 12 months after the completion of a treatment regimen), and the treatment of pseudofolliculitis barbae for all Fitzpatrick skin types.